|
RECONCILIATION OF GAAP RESEARCH AND DEVELOPMENT EXPENSES TO NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES
| |||||||||||||||
| Three Months Ended December 31, | Nine Months Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Research and development expenses, as reported | $ | 266.0 | $ | 282.4 | $ | 857.1 | $ | 820.0 | |||||||
| Share-based compensation expense | (24.4 | ) | (21.2 | ) | (71.0 | ) | (61.1 | ) | |||||||
| Other adjustments | (0.1 | ) | (0.2 | ) | (0.5 | ) | (0.6 | ) | |||||||
| Non-GAAP research and development expenses | $ | 241.5 | $ | 261.0 | $ | 785.6 | $ | 758.3 | |||||||
| GAAP research and development expenses as a percentage of net sales | 15.1 | % | 13.0 | % | 13.6 | % | 13.2 | % | |||||||
| Non-GAAP research and development expenses as a percentage of net sales | 13.7 | % | 12.0 | % | 12.5 | % | 12.2 | % | |||||||
